期刊文献+

拉米夫定治疗乙型肝炎相关失代偿期肝硬化的进展 被引量:3

下载PDF
导出
摘要 乙型肝炎病毒在体内的复制引起肝炎、肝硬化,拉米夫定是目前抗HBV的主要药物之一.拉米夫定通过抑制或干扰HBV病毒复制过程中反转录酶的活性而发挥其抗HBV 作用,可以延缓慢性乙型病毒性肝炎患者进展为失代偿期肝硬化的进程.对于失代偿期肝硬化患者,拉米夫定可以改善肝脏储备功能和生存率,降低原发性肝癌的发生率,而且安全、有效.
出处 《世界华人消化杂志》 CAS 2004年第7期1682-1684,共3页 World Chinese Journal of Digestology
基金 国家自然科学基金攻关项目 No.C03011402 No.C30070689.No.C39970674 No.C39900130军队"九 五"科技攻关项目 No.98D063军队回国留学人员启动基金项目 No.98H038军队"十 五"科技攻关青年基金项目 No.01Q138军队"十 五"科技攻关面上项目 No.01MB135
  • 相关文献

参考文献15

二级参考文献76

  • 1刘金鑫 韩永年 病毒变异的临床意义 见 刘克洲 陈智 主编.人类病毒性疾病[M].北京:人民卫生出版社,2002.45-54.
  • 2戴志澄 祁国明 等.乙肝病毒性肝炎的流行特征,中国病毒性肝炎血清流行病学调查1992-1995[M].北京:科学技术文献出版社,1997.39-59.
  • 3[1]Lai CL, Chien RN, Leung NWY, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med, 1998,339(2) :61 - 68.
  • 4[3]Villeneuve JP, Condreay LD, Willems B, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology, 2000,31(1) :207 - 210.
  • 5[4]Perrillo RP,Wright T,Rakela J,et al.A multicenter United Stated-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis. Hepatology, 2001,33 ( 2 ): 424 - 432.
  • 6[5]Yao Fy, Terrault NA, Freise C, et al. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation:A comparative study using a matched, untreated cohort. Hepatology, 2001,34(2 ): 411 - 416.
  • 7[7]Liaw YF, Chien RN,Yeh CT, et al. Acute exacerbation and heptitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology, 1999,30 (2): 567 - 572.
  • 8Peters MG, Singer G, Howard T, et al. Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: durable response after orthotopic liver transplantation on adefovir dipivoxil and hepatitis B immune globulin.Transplantation. 1999, 68:1912-1914.
  • 9Schalm SW, Heathcote J, Cianciara J, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut, 2000, 46: 562-568.
  • 10Jardi R, Buti M, Rodriguez-Frias F, et al. Rapid detection of lamivudine-resistant hepatitis B virus polymerase gene variants. J virol Methods, 1999, 83: 181-187.

共引文献253

同被引文献20

  • 1王磊,闫杰,张照华,王晶波,杜以真,李晓迎,王耀宗.拉米夫定治疗慢性乙型肝炎患者YMDD变异及影响因素的研究[J].中华肝脏病杂志,2004,12(10):585-588. 被引量:27
  • 2无.慢性乙型肝炎防治指南[J].实用肝脏病杂志,2006,9(1):8-18. 被引量:825
  • 3张定凤.乙型肝炎抗病毒治疗的前瞻[J].中华肝脏病杂志,2006,14(7):483-488. 被引量:30
  • 4Villeneuve JP, Condreay LD, Willems B, Pomier-Layrargues G, Fenyves D, Bilodeau M, Leduc R, Peltekian K, Wong F, Margulies M, Heathcote EJ. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B.Hepatology 2000; 31:207-210.
  • 5Kapoor D, Guptan RC, Wakil SM, Kazim SN, Kaul R, Agarwal SR, Raisuddin S, Hasnain SE, Sarin SK. Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis. J Hepatol 2000; 33:308-312.
  • 6Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, Lim SG, Wu PC, Dent JC, Edmundson S, Condreay LD, Chien RN. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates:results after 3 years of therapy. Hepatology 2001; 33:1527-1532.
  • 7Dienstag JL Goldin RD, Heathcote EJ, Hann HW, Woessner M, Stephenson SL, Gardner S, Gray DF, Schiff ER.Histological outcome during long-term lamivudine therapy.Gastroenterology 2003; 124:105-117.
  • 8Manolakopoulos S, Karatapanis S, Elefsiniotis J, Mathou N,Vlachogiannakos J, Iliadou E, Kougioumtzan A, Economou M, Triantos C, Tzourmakliotis D, Avgerinos A. Clinical course of lamivudine monotherapy in patients with decompensated cirrhosis due to HBeAg negative chronic HBV infection. Am J Gastroenterol 2004- 99:57-63.
  • 9Wang JH, Lu SN, Lee CM, Lee JF, Chou YP. Fatal hepatic failure after emergence of the hepatitis B virus mutant during lamivudine therapy in a patient with liver cirrhosis. Scand J Gastroenterol 2002; 37:366-369.
  • 10Song BC, Suh DJ, Lee HC, Chung YH, Lee YS. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000;32:803-806.

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部